Phico Therapeutics

Phico Therapeutics is a biotechnology company developing a novel platform technology which it believes could form the basis for a new generation of antibiotics to overcome antibacterial resistance.

Our SASPject™ platform delivers pan-spectrum anti-bacterial proteins called small acid-soluble spore proteins, or SASPs, to selected bacterial species using engineered bacterial viruses (bacteriophages). SASPject™ works by injecting a gene that encodes SASP directly into targeted bacteria.  The injected gene directs the targeted bacteria to produce SASPs, which then bind to bacterial DNA and inactivate it.  SASPs “turn off” DNA so the targeted bacterial cell cannot metabolise or reproduce.  The immune system can then remove the bacteria from the body.

SASPs bind to all bacterial DNA, irrespective of the sequence of that DNA.  Spontaneous mutations in DNA, or the import of new DNA that gives new characteristics to the bacterial cell, are key ways in which bacteria develop resistance to antibiotics. Neither of these strategies affects the ability of SASP to bind to and inactivate bacterial DNA.